Amnis Receives Broad Patent Coverage for Diagnostic Cell Imaging

SEATTLE, April 20 /PRNewswire/ -- Amnis Corporation, a manufacturer of
advanced cell imaging systems, announced today that it has received U.S.
patent 7,522,758. The patent, entitled Blood and Cell Analysis Using an
Imaging Flow Cytometer, broadly covers diagnostic uses of multispectral cell
imaging in flow or on slides and expands the company's intellectual property
estate to 32 issued U.S. patents plus multiple foreign counterparts.

"Amnis' ImageStream(R) platform was designed to achieve tremendous speed and
high fluorescence sensitivity while providing rich diagnostic information in
the form of multiple images per cell," remarked William Ortyn, Amnis'
co-founder and Chief Operations Officer. "With its ability to image hundreds
of thousands of cells in minutes, directly in flow, ImageStream combines the
diagnostic strengths of high resolution microscopy and flow cytometry in a
single platform," added Ortyn.

"Our technology is a natural fit for the minimally-invasive diagnostic
analysis of cells in bodily fluids. ImageStream enables the identification and
functional analysis of even extremely rare cells that are indicative of
disease, such as circulating tumor cells," said David Basiji, Ph.D., Amnis'
President and Chief Executive Officer. Basiji added, "We are actively
collaborating with our clinical partners on the development of diagnostic
applications and are pleased that we now have broad intellectual property in
multiple diagnostic areas."

About Amnis: Amnis Corporation, headquartered in Seattle, WA, develops,
manufactures and markets instrumentation for high speed cell imaging for
research and diagnostic markets.

SOURCE Amnis Corporation

David Basiji, President and Chief Executive Officer of Amnis Corporation,
+1-206-374-7000, fax, +1-206-576-6895, marketing@amnis.com